InvestSMART

Cyclopharm Limited (ASX:CYC)

ALERT: Price-sensitive ASX Announcement for CYC
Current share price for CYC : $0.600 -0.15 (-20%)+
Announcement
Release
31 Mar 2026 8:42AM
Price at Release
$0.750
Full Release
download
Summary
Cyclopharm Limited has provided an update on its expansion in the United States, highlighting significant growth in Technegas® installations at major health institutions like Mass General Brigham and the University of North Carolina Health System. New agreements have also been signed with the Medical University of South Carolina and Stony Brook University Health System. The company's US strategy focuses on establishing reference sites, increasing regional presence, and expanding through large healthcare networks. Currently, there are 50 installations in the US, with additional sites under contract or review. Technegas® has been included in draft clinical guidelines, anticipated to further enhance its adoption and utilization across the US market.
Key Points
  • Cyclopharm Limited is expanding its Technegas® installations in the USA.
  • Recent installations included prestigious institutions like Mass General Brigham and University of North Carolina Health System.
  • The company has signed new agreements with institutions such as the Medical University of South Carolina and Stony Brook University Health System.
  • Cyclopharm’s US expansion strategy involves establishing reference sites, building regional density, and expanding across integrated healthcare networks.
  • As of 31 March 2026, Cyclopharm has 50 revenue-generating installations and many more in various stages of contracting and review.
  • Technegas® is recognized in draft clinical guidelines as a preferred ventilation imaging agent, expected to boost its adoption in the US.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.